Meiji launches Episil in Japan

Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) launched episil (SP-3) in Japan to treat pain associated with oral mucositis (OM).

Meiji has rights to commercialize the drug in Japan from Solasia Pharma K.K. (Tokyo:4597), which has rights in the territory from Camurus AB (SSE:CAMX). Japan's Ministry of Health, Labour and Welfare (MHLW) approved the drug in July (see BioCentury, Aug. 4, 2017)...